Altris AI

Name: Altris AI
Address: Chicago, IL, US
Telephone: +13127576272
Price range: $

AI Decision Support for OCT Analysis that elevates Optometry, Ophthalmology, and Pharma

We are developing an AI platform designed to improve diagnostic in ophthalmology, which allows doctors to predict and catch retinal diseases early.

04/24/2026

This year, is featured in 2 research abstracts at the Association for Research in Vision and Ophthalmology (ARVO).

✅ Abstract/Presentation Title: Pilot study on the use of AI to identify and pre-screen patients for an interventional Geographic Atrophy clinical trial

Presentation Type: Poster Session
Session Number: 150
Session Date/Times: May 3, 2026, from 3:15 PM to 5:00 PM

✅ Abstract/Presentation Title: Human Retinal GCL/IPL Thickness as a Structural Indicator of Systemic Inflammation: A Proof-of-Concept OCT–Cytokine Analysis Within the IICM™Platform

Presentation Type: Poster Session
Session Number: 513
Session Date/Times: May 7, 2026, from 8:00 AM to 9:45 AM

Attend to learn how AI Decision Support for OCT Analysis accelerates patient enrollment, reduces screen failure rate, & elevates ophthalmic research.

04/23/2026

Photobiomodulation (PBM) therapy is redefining the standard of care for Dry AMD. Altris AI brings clarity & objectivity to its results.

PBM adoption is accelerating across eye care centers. PBM offers a promising way to slow Dry AMD progression and preserve quality of life. But innovation alone isn’t enough—without objective measurement, it’s impossible to prove impact or guide treatment decisions. Patients want evidence. Clinicians need precision.

Drusen are one of the most informative biomarkers in PBM-treated patients. That is why we created a separate function for drusen count. By automatically quantifying their number, volume, and area - and tracking changes over time - Altris AI turns OCT scans into clear, actionable insights, showing exactly how patients respond to therapy.

With Altris AI, clinicians can:
✅ Detect 4 types of drusen — soft, hard, confluent, and reticular pseudodrusen
✅ Auto-calculate drusen across all B-scans
✅ Quantify drusen volume and area
✅ Track progression over time via maps, graphs, and percentages
✅ Automatically assess Ellipsoid Zone and RPE disruption
The result? Objective, data-driven insight into every patient's response to PBM therapy — empowering smarter clinical decisions.

AI doesn't replace clinical expertise. It gives it the evidence it deserves.
hashtag

04/17/2026

FinnGen is the largest medical research project in Finland, whose principal aim is to improve our understanding of the genetic background of diseases. The University of Helsinki is the organization responsible for the FinnGen initiative.

Altris AI supported FinnGen in large-scale OCT data analysis, processing 40,000 OCT scans. As a result, FinnGen received structured, research-ready quantitative data in XLSX format, covering 30+ retinal pathologies and 40+ biomarkers across the target population.

Data security was a critical component of the project, including full anonymization, encryption at rest, and secure data transfer protocols.

Many reserach organizations do not want to rely on manual OCT analysis anymore. Vendor-neutral OCT compatibility, combined with the ability to analyze large volumes of data at scale, is what Altris AI, an AI Decision Support platform for OCT analysis, offers to research institutions, academic organizations, and pharmaceutical companies.

04/15/2026

High screen failure rates in ophthalmic clinical trials are not just costly - they delay enrollment before studies can even gain momentum.

, an FDA-cleared AI-powered decision support platform for OCT analysis, automates OCT-based eligibility assessment, helping you identify qualified patients faster and reduce screen failures.

We’ll be at this year. If accelerating patient enrollment and improving trial efficiency are priorities for your team, stop by Booth 5026 - Grant Schmid, our Head of BD, would be glad to connect.
,

04/07/2026

Big news! Altris AI has obtained the Kingdom of Saudi Arabia Medical Device Marketing Authorization (M**A) from SFDA - هيئة الغذاء والدواء: Saudi Food and Drug Authority. Altris AI is now approved as an AI-powered Clinical Decision Support System in the Kingdom.

This matters. We respect local laws and regulatory frameworks in every country we enter. Patient safety and the trust of Eye Care Professionals is not a checkbox: it is the basis for everything we build.

M**A from SFDA - هيئة الغذاء والدواء is not just a formality. It reflects strict regulatory standards designed to protect patients and ensure safe clinical use. To receive this authorization, our AI-powered Clinical Decision Support System demonstrated:

✅ proven safety and clinical reliability
✅ clear intended medical use
✅ validated performance and accuracy
✅ strong risk management and data security compliance
✅ a certified quality management system (QMS)
✅ real clinical value for patient care

Altris AI was designed to support clinicians with OCT analysis, provide a second opinion in complex cases, and highlight early changes. Adding an extra layer of confidence to OCT analysis. Now, for the Eye Care Specialists from the Kingdom of Saudi Arabia as well!

03/27/2026

«AI in Healthcare» is far from being monolithic. There are different tools for different purposes.

Tools like ChatGPT Health, MedLlama, and MedGemma represent a valuable class of AI: broad, flexible, and increasingly capable of supporting general clinical knowledge. Built to give generalized plausible answers. To patients mostly.

is solving a different problem entirely.

Built exclusively for OCT analysis, it detects 30+ retinal pathologies and 40+ biomarkers across scans from multiple device manufacturers. It uses an exclusive, extensive dataset of carefully labelled OCT scans. It works with DICOMs and raw files from 9 OCT. Altris AI has undergone serious regulatory review to receive FDA clearance, CE certificate, Health Canada and be HIPAA and GDPR-compliant.

It’s a precision clinical instrument created for eye care specialists by eye care specialists.

03/25/2026

“That lights up like a Christmas tree!” - Bobby Saenz OD, MS, FAAO, AI enthusiast and daily user of Altris AI part of Altris Inc.shares his experience using the Geographic Atrophy progression module.

At Altris AI, we’ve developed a dedicated module to monitor Geographic Atrophy progression with precise measurements in millimeters (mm) and percentages (%), supported by intuitive maps and graphs.

The platform also enables the tracking of over 40 retinal biomarkers. We understand how critical objective, quantitative data is when managing complex pathologies.

03/19/2026

is the Winner of the 2026 Innovation Challenge!

We’re thrilled to celebrate Altris AI as the Judge’s Winner of the 2026 VSP Vision, announced live on March 13 at .expo !

Altris AI is a clinical-grade SaaS platform that acts as a «second set of eyes» for eye care specialists, identifying more than 70 retinal biomarkers from OCT scans — helping providers match patients to the right treatments, devices, and clinical trials with objective, data-driven precision.

The company was recognized for its clinical impact, technological sophistication, and potential to transform the eyecare experience.

This win is a testament to what’s possible when cutting-edge AI meets real-world clinical need. The future of eye care is here, and Altris AI is leading the way.

03/10/2026

Photobiomodulation therapy is reshaping how ECPs treat Dry AMD. And is making it measurable.

More and more eye care centers are adopting PBM therapy to slow disease progression and improve the quality of life for patients with Dry AMD. But with any innovative treatment, monitoring effectiveness isn’t optional. Patients also want to see the results.

That’s where AI Decision Support for OCT analysis comes in.

Drusen are emerging as one of the key biomarkers for tracking PBM treatment outcomes — their number, volume, area, and progression over time tell the story of whether therapy is working.

With Altris AI, clinicians can:
✅ Detect 4 types of drusen — soft, hard, confluent, and reticular pseudodrusen
✅ Auto-calculate drusen across all B-scans
✅ Quantify drusen volume and area
✅ Track progression over time via maps, graphs, and percentages
✅ Automatically assess Ellipsoid Zone and RPE disruption
The result? Objective, data-driven insight into every patient’s response to PBM therapy — empowering smarter clinical decisions.

AI doesn’t replace clinical expertise. It gives it the evidence it deserves.

03/09/2026

We’re proud to share that has been selected as one of 4 finalists for the Innovation Challenge 2026 🎉 at .expo.

Next week, Grant Schmid will be taking the stage live at Vision Expo — and we couldn’t be more energized heading into it.

✅ If you want to try Altris AI: Booth IC37

For us, this is about more than a competition. It’s about accelerating the future of eye care diagnostics: at Altris AI, it’s always been about the patient - the most important person on the other side of the screen. We exist to catch what’s easy to miss on retina scans, earlier than ever before, so that clinicians can focus on what truly matters: making the right call, at the right time. On Time.

We are not just building technology. We are raising the bar for what eye care should be.

If you’re attending Vision Expo, Grant Schmid, representing Altris AI, would love to connect in person to tell you more about it.

02/24/2026

We’re proud to announce that Altris AI has received approval from Health Canada. For a company scaling globally, regulatory approvals are not checkboxes. They are growth enablers.

Health Canada approval strengthens our global position, supports future regulatory pathways, and shows that Altris AI is built for real-world clinical practice. It's a safe and reliable AI Decision Support for OCT analysis that elevates optometry, ophthalmology, and pharma.

Altris AI's clinical and technical validation withstands Health Canada | Santé Canada regulatory review, which includes:

• Clinical evidence
• Risk management
• Cybersecurity
• Quality management systems
• Intended use claims

It’s external confirmation that our AI Decision Support platform for OCT analysis meets medical device standards. This is how AI in eye care moves from innovation to infrastructure.

Address

Chicago, IL

Telephone

+13127576272

Website

https://demo.altris.ai/, https://www.altris.ai/

Alerts

Be the first to know and let us send you an email when Altris AI posts news and promotions. Your email address will not be used for any other purpose, and you can unsubscribe at any time.

Contact The Business

Send a message to Altris AI:

Shortcuts

Featured

Dunright Renovations
2200 S. Main Street Suite # 302,

Want your business to be the top-listed Engineering Company in Chicago?